2021
Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2018
Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. Gastroenterology 2018, 154: 1309-1319.e7. PMID: 29305933, PMCID: PMC5880739, DOI: 10.1053/j.gastro.2017.12.024.Peer-Reviewed Original ResearchConceptsWeight loss medicationsCardiometabolic risk profileHigh-density lipoprotein cholesterolWaist circumferenceDrug AdministrationSystematic reviewRisk profileLipoprotein cholesterolHemoglobin A1cObese adultsCholesterol profileSystolic/diastolic BPCardiometabolic risk factorsNetwork Meta-AnalysisRandomized clinical trialsQuality of evidenceLow-density lipoproteinModest decreaseOutcomes of interestEffect of foodLong-term useMinimal effectLiraglutide useOrlistat useBlood pressure
2017
Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy
Cheeran D, Khan S, Khera R, Bhatt A, Garg S, Grodin JL, Morlend R, Araj FG, Amin AA, Thibodeau JT, Das S, Drazner MH, Mammen PPA. Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy. Journal Of The American Heart Association 2017, 6: e006340. PMID: 29042427, PMCID: PMC5721845, DOI: 10.1161/jaha.117.006340.Peer-Reviewed Original ResearchConceptsDuchenne muscular dystrophyDMD patientsPrognostic factorsDMD populationCardiac biomarkersHigh-risk cardiovascular populationLower body mass indexAdult DMD patientsHeart failure medicationsPredictors of deathAlanine aminotransferase levelsElevated cardiac biomarkersPoor prognostic factorMaximum inspiratory pressureBody mass indexElectronic medical recordsCardiomyopathy clinicMedian followAminotransferase levelsBaseline characteristicsCardiovascular populationRetrospective cohortConsecutive patientsMass indexWorse prognosis
2014
“Inflammation and arterial stiffness in humans”
Jain S, Khera R, Corrales–Medina V, Townsend RR, Chirinos JA. “Inflammation and arterial stiffness in humans”. Atherosclerosis 2014, 237: 381-390. PMID: 25463062, DOI: 10.1016/j.atherosclerosis.2014.09.011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPrimary inflammatory diseaseArterial stiffnessArterial stiffeningInflammatory diseasesPrimary inflammatory conditionsAnti-inflammatory interventionsRole of inflammationAnti-inflammatory therapyEffect of statinsEffects of inflammationPotential therapeutic targetCardiovascular morbiditySubclinical inflammationInflammatory conditionsGeneral populationTherapeutic targetInflammationEstablished markerNormal adultsPotential mechanismsDiseaseHypertensionMorbidityStatinsArtery
2012
Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE
Das N, Biswas B, Khera R. Membrane-Bound Complement Regulatory Proteins as Biomarkers and Potential Therapeutic Targets for SLE. Advances In Experimental Medicine And Biology 2012, 735: 55-81. PMID: 23402019, DOI: 10.1007/978-1-4614-4118-2_4.ChaptersConceptsComplement regulatory proteinsMembrane-bound complement regulatory proteinsTherapeutic targetDisease activityAutoimmune disordersAmerican Rheumatology AssociationAntidouble-stranded DNADisease activity markersSLE disease activitySystemic autoimmune disorderSystemic lupus erythematosusPotential therapeutic targetGene knockout miceLevels of DAFAntinuclear antibodiesLupus erythematosusMultiorgan involvementRheumatology AssociationInflammatory disordersReproductive ageActivity markersNoninvasive biomarkersDiagnostic criteriaKnockout miceSLE